Question of the Day October 9, 2014 Did the pressure on the state boards of pharmacy just become huge with the FDA sending letters where a compounding pharmacy claims or has patient-specific prescriptions and the FDA inpects them and finds issues? How bad will it look if a state board of pharmacy does not take action once on notice from the FDA? In the future, how can Congress blame the FDA if one of these pharmacies referred to the state is not deal with by the state and ultimately sales contaminated compounds especially after compounders have been the biggest line drawers in the sand of 503A and 503B jurisdiction? Won't this be just the evidence Congress will need to give the FDA complete jurisdiction over compounding pharmacies? Isn't this a very smart move on the FDA's part?